Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Leishmaniasis

Elinor M Moore and Diana N Lockwood
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.11-5-492
Clin Med October 2011
Elinor M Moore
Hospital for Tropical Diseases, University College London Hospital
Roles: Specialist registrar, tropical medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana N Lockwood
Hospital for Tropical Diseases, University College London Hospital; London School of Tropical Medicine and Hygiene
Roles: Professor of tropical medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Key Words
  • mucocutaneous leishmaniasis
  • new world cutaneous leishmaniasis (NWCL)
  • old world cutaneous leishmaniasis (OWCL)
  • visceral leishmaniasis

Key points

  • Suspect visceral leishmaniasis in patients with chronic fever, pancytopaenia and splenomegaly

  • Suspect cutaneous leishmaniasis in patients with chronic ulcers in exposed areas of the body

  • Elicit a travel history, including enquiries about travel to the Mediterranean basin

  • Immunosuppression alters disease presentation and management

  • Leishmaniasis is uncommon in the UK; expert help exists though

There are an estimated 1.5–2 million new cases and 70,000 deaths per year worldwide from leishmania visceral and skin diseases.1 Leishmania parasites are transmitted to humans by the bite of the phlebotomus sandfly. It is uncommon in the UK and most physicians are unfamiliar with the clinical presentation and management; there were only 58 reported cases of leishmaniasis in England, Wales and Northern Ireland in 2005.2 This article reviews the two main clinical types of leishmaniasis, with a focus on presentation in the UK.

Visceral leishmaniasis

The greatest disease burden of visceral leishmaniasis (VL) worldwide is in India and Sudan (Fig 1), but many patients in the UK have contracted their infections from the Mediterranean basin, sometimes after relatively short exposure on holiday. The incubation period from infected sandfly bite to disease presentation is typically several months but can be longer.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Geographical distribution of visceral leishmaniasis. Reproduced with permission from the World Health Organization.1

Clinical features

Patients with VL present with chronic fever, splenomegaly and pancytopenia (Box 1). Weight loss is common and patients may present with the sequelae of pancytopenia (bleeding, severe anaemia and intercurrent infections). Clinical examination may also reveal hepatomegaly and lymphadenopathy. Other abnormalities include hypoalbuminaemia and polyclonal hypergammaglobulinaemia (which may cause false-positive results with autoantibody tests).

Box 1.

Visceral leishmaniasis (VL) case history.


Embedded Image

Diagnosis

Diagnosis of VL can be made by direct visualisation of parasites via microscopy or culture. The best tissue to examine is a bone marrow biopsy, although splenic aspirates are used at specialised institutions because they provide additional information about the load of infection. These should be performed only by those with experience because of the risk of bleeding. Specialised parasitology laboratories can also perform polymerase chain reaction (PCR) tests on these samples to detect leishmania DNA. Two serology tests to look for antileishmania antibodies are available:

  • The direct agglutination test: a semiquantitative agglutination test using killed leishmania parasites and increasing dilutions of patients' blood or serum (sensitivity 92.7–96.4%).

  • The RK39 dipstick: a qualitative test using recombinant leishmania antigen with patients' blood (sensitivity 87.7–97.1%).3

Experience is needed to interpret these tests. They remain positive despite adequate VL treatment, thus cannot be used to assess cure post-treatment or following relapse. In endemic areas the specificity can be low, as exposed populations without clinical disease may have an antibody response (up to 32% of the population in some areas). Nearly half of patients with HIV will have false negative serology.4

Treatment

The first-line drug for treating VL in the UK is liposomal amphotericin B. The current treatment regimen which gives a 95% cure rate is 20 mg/kg in five doses over 10 days (ie 4 mg/kg/day on days 1, 2, 3, 5 and 10).5 Trials from India have reported a 90% cure rate after a single dose of liposomal amphotericin B.6 Side effects include renal impairment, hypokalaemia, infusion reactions and anaemia.

Other treatments such as sodium stibogluconate (SSG) are still widely used in other parts of the world because they are cheap and easy to use.7 Combination treatments have been proposed to avoid parasite resistance to therapy which has been reported in patients from India.8

Drug treatments for VL, including those used in the UK when patients are intolerant of, or poorly responsive, to liposomal amphotericin B, are summarised in Table 1.9

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Drug treatment for visceral leishmaniasis.

Visceral leishmaniasis in immunosuppressed patients

The presentation and management of VL is different in immunosuppressed patients. Worldwide, HIV is the main immunosuppressive influence seen in conjunction with VL, but other immunosuppressive states seen in patients with VL in the UK are advanced age, immunosuppressive therapy and treatment with tumour necrosis factor antibody therapies.

The main clinical features of VL may be absent or atypical, and there may be evidence of leishmania parasites in unusual body sites (eg skin, gut, genitourinary tract). Establishing the diagnosis of VL therefore may be more difficult.10 Abnormal tissue from any body site should be examined for evidence of leishmania parasites if the patient has been in an endemic area and is immunosuppressed.

Patients who remain immunosuppressed may respond poorly to the standard treatment protocols, so an attempt to improve their immune status is a key strategy in their management. If this is not possible, long-term prophylactic treatment may be considered after the initial treatment course as there is a high risk of recurrence after apparently successful treatment. When patients fail first-line treatment courses, second-line therapy needs to be considered from the options listed in Table 1. There is little evidence to guide the choice of prophylactic and second-line treatment courses and management of these patients should be discussed with an expert.

Cutaneous leishmaniasis

Several species of Leishmania protozoa can cause localised cutaneous leishmaniasis (CL). A simple geographical classification (Fig 2) divides species into ‘old world’ species, from Africa, the Middle East and Central Asia (OWCL), and ‘new world’ species, from South and Central America (NWCL).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Geographical distribution of cutaneous leishmaniasis. Reproduced with permission from the World Health Organization.1

Of the patients seen from 1998–2009 at the Hospital for Tropical Diseases, London, 40% (90) had OWCL and 60% (133) had NWCL. Of the OWCL patients, 71% were tourists to the Mediterranean, 36% migrants or visiting friends and relatives, and 17% were military personnel. Of the NWCL, 44% were backpackers and 39% soldiers (Wall EC unpublished data).

Presentation and diagnosis

CL typically presents with a nodule(s) at the sandfly bite(s) site that enlarges and ulcerates over several weeks. The incubation period can be months to years (usually <2 years) after the initial bite. The lesions are usually in exposed body areas such as the face and hands (Fig 3). The edge of the lesion is well demarcated and raised, and there may be satellite lesions in the same area. The ulcer base may be crusted, bloody or with pus. Occasionally there is a nodular lymphangitis that can be palpated in the surrounding area.

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Early Cutaneous leishmaniasis lesion with a raised indurated edges around a central ulcer. Papules can be seen spreading from the lesion. Figure courtesy of Colonel Mark Bailey.

Spontaneous resolution can occur, so at the time of clinical presentation there may be signs of healing, particularly in the centre of the lesion (up to 50–75% cases have healed within 4–6 months in some OWCL species11). The differential diagnosis for these lesions includes infected insect bites, mycobacterial skin infections and malignancy.

Diagnosis

Diagnosis of CL is by direct visualisation of the parasites via microscopy and culture of a biopsy from the ulcer edge. Typical histopathological features are granulomatous inflammation and leishmania amastigotes. Leishmania DNA can be detected by PCR, so confirming infection and identifying the leishmania species. This is important if viannia species is suspected and the patient is at risk of mucocutaneous disease.

PCR testing has also shortened the time to diagnosis. At the HTD parasitology laboratory, microscopy is 62–77% sensitive and culture takes on average 11.6 days to a definitive result, whereas PCR results take on average eight days to process (Wall EC; unpublished data). Lesions difficult to biopsy (eg facial, ear, finger) can be scraped or aspirated, although the diagnostic yield is lower.

Mucocutaneous leishmaniasis

Mucocutaneous leishmaniasis (MCL) is caused by the Leishmania viannia subgroup of species found in South America. So-called ‘espundia’, occurs in 1–10% of cases of NWCL in endemic areas.12

Presentation

Patients present with nasal stuffiness and bleeding, ulceration and perforation of the nasal septum from mucosal inflammation and destruction (Box 2). This can occur at the same time as the NWCL skin ulcer or many months after it has healed. Left untreated, this can progress to widespread destruction of the palate, lips and cheeks.

Box 2.

Mucocutaneous leishmaniasis (MCL) case history.


Embedded Image

Treatment for cutaneous and mucocutaneous leishmaniasis

The first-line treatment for both CL and MCL is sodium stibogluconate (SSG) although several factors need to be considered in choosing the best route of administration and length of treatment (Fig 4). The side effects of intravenous (iv) SSG include myalgia, nausea, raised transaminases and amylase, and cardiac conduction abnormalities.13

Fig 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 4.

Treatment of cutaneous leishmaniasis (CL). iv = intravenous; NWCL = New World CL; OWCL = Old World CL, PCR = polymerase chain reaction; SSG = sodium stibogluconate.18,19

The risk of these side effects is justified in NWCL because of the risk of subsequent destructive mucocutaneous spread if left untreated. Intralesional infiltration of SSG avoids these toxicities, but needs an experienced physician to administer it and can be transiently painful during the injections. Most OWCL can be treated with intralesional SSG, although very large or numerous OWCL lesions that will need repeated and extensive weekly intralesional SSG may be treated with iv SSG. Patients with pre-existing cardiac conduction defects or hepatic dysfunction are more likely to develop adverse effects from iv SSG.

Alternative treatments exist, but the evidence for their benefit is mostly limited to small case reports. Physical treatments for OWCL (eg curettage, cryotherapy and thermotherapy) seem to have unfavourable outcomes such as secondary infection, larger scars with depigmentation and risk of dissemination of CL. Topical treatments such as paromomycin seem ineffective. There was hope for oral fluconazole as a treatment for OWCL after a well published trial14 but several subsequent studies have shown disappointing results. Alternative treatments for NWCL include amphotericin B and miltefosine, but neither has proven cure rates equivalent to SSG.15–17

Summary

Leishmaniasis is an uncommon infectious disease in the UK with a variety of clinical presentations. Physicians should remember to consider this diagnosis in patients with an appropriate travel history (including the Mediterranean basin) and seek help with diagnostics from a specialised parasitology laboratory. Treatment regimens may be unfamiliar to the general physician, and thus should also be discussed with an expert.

Leishmaniasis specialist services in the UK

Hospital for Tropical Diseases, London

Specialist physician: Professor DN Lockwood

Specialist parasitologist: Professor PL Chiodini

Liverpool School of Tropical Medicine

Specialist physician: Dr T O'Dempsey Specialist parasitologist: Dr W Bailey

The Infectious Diseases Unit, Birmingham Heartlands Hospital

Specialist physician: Major MS Bailey

  • © 2011 Royal College of Physicians

References

  1. ↵
    World Health Organization. Leishmaniasis disease burden. www.who.int/leishmaniasis/en
  2. ↵
    Foreign travel associated illness in England, Wales and Northern Ireland, 2007 report. Arthropod borne diseases: 57–59. www.hpa.org.uk
  3. ↵
    1. Chappuis F,
    2. Rijal S,
    3. Soto A,
    4. Menten J,
    5. Boelaert M
    . A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstik for visceral leishmaniasis. BMJ 2006; 333: 723–6doi:10.1136/bmj.38917.503056.7C
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Lockwood DN,
    2. Sundar S
    . Serological tests for visceral leishmaniasis. BMJ 2006; 333: 711–2doi:10.1136/bmj.38989.567083.BE
    OpenUrlFREE Full Text
  5. ↵
    1. Davidson RN,
    2. di Martino L,
    3. Gradoni L,
    4. et al
    . Short-course treatment of visceral leishmaniasis with liposomal amphotericin B. Clin Infect Dis 1996; 22: 938–43doi:10.1093/clinids/22.6.938
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Sundar S,
    2. Chakravarty J,
    3. Agarwal D,
    4. Rai M,
    5. Murray HW
    . Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504–12doi:10.1056/NEJMoa0903627
    OpenUrlCrossRefPubMed
  7. ↵
    1. Seaman J,
    2. Mercer AJ,
    3. Sondorp HE,
    4. Herwaldt BL
    . Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996; 124: 664–72
    OpenUrlCrossRefPubMed
  8. ↵
    1. Sundar S,
    2. More DK,
    3. Singh MK,
    4. et al
    . Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31: 1104–7doi:10.1086/318121
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Moore EM,
    2. Lockwood DN
    . Treatment of visceral leishmaniasis. J Glob Infect Dis 2010; 2: 151–8
    OpenUrlCrossRefPubMed
  10. ↵
    1. Pintado V,
    2. Martin-Rabadan P,
    3. Rivera ML,
    4. Moreno S,
    5. Souza E
    . Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 2001; 80: 54–73
    OpenUrlCrossRefPubMed
  11. ↵
    1. Morizot G,
    2. Delgiudice P,
    3. Caumes E,
    4. et al
    . Healing of old world cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution? Am J Trop Med Hyg 2007; 76: 48–52
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Marsden PD
    . Mucosal leishmaniasis (‘espundia’ Escomel 1911). Trans R Soc Trop Med Hyg 1986; 80: 859–76
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Lawn SD,
    2. Armstrong M,
    3. Chilton D,
    4. Whitty CJ
    . Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers. Trans R Soc Trop Med Hyg 2006; 100: 264–9doi:10.1016/j.trstmh.2005.03.012
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Alrajhi AA,
    2. Ibrahim EA,
    3. De Vol EB,
    4. et al
    . Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346: 891–5
    OpenUrlCrossRefPubMed
  15. ↵
    1. Soto J,
    2. Arana BA,
    3. Toledo J,
    4. et al
    . Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266–72doi:10.1086/383321
    OpenUrlAbstract/FREE Full Text
    1. Brown M,
    2. Noursadeghi M,
    3. Boyle J,
    4. Davidson RN
    . Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 2005; 153: 203–5doi:10.1111/j.1365-2133.2005.06670.x
    OpenUrlCrossRefPubMed
  16. ↵
    1. Reithinger R,
    2. Dujardin JC,
    3. Louzir H,
    4. et al
    . Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581–96doi:10.1016/S1473-3099(07)70209-8
    OpenUrlCrossRefPubMed
  17. ↵
    1. Herwaldt B
    . Leishmaniasis. Lancet 1999; 354: 1191–9doi:10.1016/S0140-6736(98)10178-2
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bailey MS,
    2. Green AD,
    3. Ellis CJ,
    4. et al
    . Clinical guidelines for the management of cutaneous leishmaniasis in British military personnel. J R Army Med Corps 2005; 151: 73–80
    OpenUrlFREE Full Text
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Leishmaniasis
Elinor M Moore, Diana N Lockwood
Clinical Medicine Oct 2011, 11 (5) 492-497; DOI: 10.7861/clinmedicine.11-5-492

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Leishmaniasis
Elinor M Moore, Diana N Lockwood
Clinical Medicine Oct 2011, 11 (5) 492-497; DOI: 10.7861/clinmedicine.11-5-492
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visceral leishmaniasis
    • Mucocutaneous leishmaniasis
    • Presentation
    • Treatment for cutaneous and mucocutaneous leishmaniasis
    • Summary
    • Leishmaniasis specialist services in the UK
    • References
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A patient with rheumatoid arthritis, cryoglobulinaemia, and an "accidental" finding
  • Google Scholar

More in this TOC Section

  • CME Tropical Medicine (123847): self-assessment questionnaire
  • The management of malaria in adults
  • Dengue
Show more CME Tropical Medicine

Similar Articles

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians